C Ray Therapeutics Highlights Integrated Radiopharmaceutical Hub Strategy in Chengdu

A LinkedIn post from C Ray Therapeutics describes how the company recently convened participants from the global radiopharmaceutical drug conjugates ecosystem at XDC 2026 in Chengdu. The post portrays Chengdu as an emerging radiopharmaceutical hub, citing infrastructure, policy support, and rapid build-out as key advantages.

According to the post, visitors toured Chengdu Medical City and were introduced to C Ray Therapeutics as a single-site radiopharmaceutical CRDMO offering process development, radiolabeling, cGMP manufacturing, and cold-chain logistics. The message emphasizes that this one-stop model is designed to support a broadening pipeline of ligands, novel isotopes, and new therapeutic modalities.

The post suggests that trends such as diversified ligand platforms and improved isotope supply, including isotopes like Ac225, Pb212, and Lu177, are converging to expand radiopharmaceutical applications. It positions C Ray Therapeutics, headquartered in Chengdu, as operating at the intersection of China’s growing capabilities and global development demand.

From an investor perspective, the content underscores C Ray Therapeutics’ intent to be a key manufacturing and development partner in the radiopharmaceutical value chain. If the company can leverage Chengdu’s ecosystem and its integrated CRDMO model, it could strengthen its competitive position in a high-growth niche, potentially attracting additional international partners and future revenue opportunities.

The post also references collaboration and engagement with organizations such as NorthStar Medical Radioisotopes, Thor Medical, Navigo, and Oncoinvent, indicating active dialogue with established industry players. While no specific contracts, funding details, or financial metrics are mentioned, the emphasis on ecosystem building and partner engagement points to a strategy focused on long-term capacity utilization and global deal flow.